Accès ouvert
2025
article
OpenAlex
Claire V Hoffmann, Yannick Le Meur, Marie‐Christine Moal, Anne Grall-Jézéquel et autres
BACKGROUND: Pneumocystis pneumonia (PCP) case clusters involving solid organ transplant (SOT) recipients have been reported worldwide. Mycophenolic acid, an immunosuppressant used to prevent rejection in SOT recipients that targets the inosine 5'-monophosphate dehydrogenase (IMPDH) protein, has been hypothesised to exert selective pressure …
fr
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Margaux Pacaud, Thibault Kervarrec, Julien Masliah‐Planchon, Anne Tallet et autres
International audience
fr
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Siriane Lefèvre, Marie‐Pierre Audrézet, Jean‐Michel Halimi, Hélène Longuet et autres
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is associated with an increased risk for developing intracranial aneurysms (IAs). We aimed to evaluate the frequency of diagnosis of IAs in the cross-sectional, population-based, Genkyst cohort, to describe ADPKD-associated IAs and to analyse the …
fr
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Claire V. Hoffmann, Gilles Nevez, Marie‐Christine Moal, Dorothée Quinio et autres
Mycophenolic acid (MPA) targets the inosine 5′-monophosphate dehydrogenase (IMPDH) of human lymphocytes. It is widely used as an immunosuppressant to prevent rejection in solid organ transplant (SOT) recipients who, incidentally, are at risk for Pneumocystis pneumonia (PCP). We hypothesized that MPA exerts …
fr
(code pays fourni par la source)
2020
article
OpenAlex
Solène Le Gal, Pierre L. Bonnet, A Huguenin, Célia Chapelle et autres
Pulmonary specimen pairs from five patients who presented with pulmonary colonization and later developed Pneumocystis Pneumonia (PcP) were retrospectively examined for P. jirovecii genotyping. A match of genotypes in pulmonary specimen pairs of three patients was observed, whereas a partial match and …
fr
(code pays fourni par la source)
2018
article
OpenAlex
Laurence Pougnet, A. Grall, Marie‐Christine Moal, Richard Pougnet et autres
International audience
fr
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
Flavio G. Vincenti, Lionel P. E. Rostaing, J.M. Boria Grinyo, Kim M. Rice et autres
BACKGROUND: In previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as compared with cyclosporine-based immunosuppression, was associated with similar patient and graft survival and significantly improved renal function in kidney-transplant recipients. Here we present the final results from this study. …
us, fr, es, ar, in, be
(code pays fourni par la source)
Accès ouvert
2016
article
OpenAlex
Annick Massart, Annaïck Pallier, Julio Pascual, Ondřej Viklický et autres
BACKGROUND: Kidney recipients maintaining a prolonged allograft survival in the absence of immunosuppressive drugs and without evidence of rejection are supposed to be exceptional. The ERA-EDTA-DESCARTES working group together with Nantes University launched a European-wide survey to identify new patients, describe them …
be, fr, es, cz, de, tr, dk, ch, at, gb, nl, il, se, it, us, si, sk, pl
(code pays fourni par la source)
Accès ouvert
2015
article
OpenAlex
Émilie Cornec-Le Gall, Marie‐Pierre Audrézet, Annick Rousseau, Maryvonne Hourmant et autres
The course of autosomal dominant polycystic kidney disease (ADPKD) varies among individuals, with some reaching ESRD before 40 years of age and others never requiring RRT. In this study, we developed a prognostic model to predict renal outcomes in patients with ADPKD …
fr, us
(code pays fourni par la source)
2014
article
OpenAlex
Yannick Le Meur, Markus Wolfgang Büchler, Ch. Mousson, Marie‐Christine Moal et autres
Everold: a multicenter randomized study for the use of everolimus in “old-for-old” renal transplantation. In elderly patients receiving a kidney graft from old donors, CNI-free protocols are interesting but expose to the risk of acute rejection. We conducted the Everold study for …
fr, jp
(code pays fourni par la source)
2014
article
OpenAlex
Gilles Blancho, Klemens Budde, Pierre Merville, Marie‐Christine Moal et autres
Background: The clinical profile of belatacept (bela) was demonstrated in two phase 3 studies; BENEFIT enrolled recipients of living donor or SCD kidneys, and BENEFIT-EXT enrolled recipients of ECD kidneys defined by UNOS criteria, anticipated CIT >24 hrs, or NHB donor. Each …
fr, de, us, es
(code pays fourni par la source)
Accès ouvert
2013
article
OpenAlex
Lionel P. E. Rostaing, Flavio G. Vincenti, Josep M. Grinyo, Kim M. Rice et autres
The Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial randomized patients receiving a living or standard criteria deceased donor kidney transplant to a more (MI) or less intensive (LI) regimen of belatacept or cyclosporine A (CsA). The 5-year results of …
fr, us, es, in, ar
(code pays fourni par la source)